Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Target Price at $12.67

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have earned a consensus recommendation of “Buy” from the ten analysts that are presently covering the firm, Marketbeat reports. Nine analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $12.67.

A number of brokerages have recently issued reports on CMPX. Guggenheim cut their price objective on shares of Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, May 9th. HC Wainwright reiterated a “buy” rating and set a $24.00 price objective on shares of Compass Therapeutics in a research note on Monday, April 21st. Raymond James Financial raised shares of Compass Therapeutics to an “outperform” rating and set a $9.00 price target for the company in a report on Tuesday, July 1st. Wedbush restated an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research report on Tuesday, April 1st. Finally, Leerink Partners raised shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $3.15 on Friday. The firm has a market capitalization of $435.58 million, a P/E ratio of -7.68 and a beta of 1.48. The stock has a 50 day moving average price of $2.41 and a two-hundred day moving average price of $2.37. Compass Therapeutics has a 52 week low of $0.87 and a 52 week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). On average, equities analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio bought a new position in shares of Compass Therapeutics in the first quarter valued at about $34,000. Birchview Capital LP bought a new stake in shares of Compass Therapeutics during the 1st quarter worth approximately $46,000. Propel Bio Management LLC bought a new stake in shares of Compass Therapeutics during the 1st quarter worth approximately $434,000. Walleye Trading LLC bought a new stake in Compass Therapeutics in the 1st quarter valued at $48,000. Finally, Walleye Capital LLC bought a new position in Compass Therapeutics during the 1st quarter worth $100,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.